Combination Treatment of C16 Peptide and Angiopoietin-1 Alleviates Neuromyelitis Optica in an Experimental Model
Table 1
C16 and Ang1 treatment reduces c-SEP and MEP latencies as well as increases their amplitudes at both 1 and 8 weeks pi.
(a)
Group
N
P
Wave amplitude (μV, mean ± SD)
1-week c-SEP
Latency (ms);
Control
13.95 ± 0.31
19.68 ± 0.17
12.39 ± 0.68
Vehicle
22.31 ± 0.32
28.99 ± 0.44
3.48 ± 0.28
C16 + Ang1
16.48 ± 0.18
20.21 ± 0.19
10.89 ± 1.32
8-week c-SEP
Latency (ms);
Control
12.88 ± 0.34
17.69 ± 0.25
14.08 ± 1.24
Vehicle
29.3 ± 1.22
37.68 ± 0.65
2.55 ± 0.16
C16 + Ang1
15.67 ± 0.06
20.59 ± 0.1
14.89 ± 0.88
(b)
Group
Latency (ms)
Wave amplitude (μV, mean ± SD)
1-week MEP
Control
6.12 ± 0.24
10.42 ± 1.22
Vehicle
6.86 ± 0.64
0.12 ± 0.03
C16 + Ang1
5.78 ± 0.15
4.45 ± 0.18
8-week MEP
Control
5.76 ± 0.23
10.09 ± 0.61
Vehicle
6.57 ± 0.95
0.72 ± 0.02
C + A + R
5.29 ± 0.8
6.33 ± 0.35
versus the vehicle-treated rats. versus the vehicle-treated rats. N: negative deflection; P: positive deflection; c-SEP: somatosensory-evoked potential; MEP: motor-evoked potential.
